US 2017/0360911 A1 · TUMOR ANTIGEN PEPTIDE

Abstract

The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.

Claims42

Dependent claims

An antigen peptide specific to cancer stem cells represented by Y0-X0-Z0, wherein

X0 is any of (1) to (4) below:
(1) a partial peptide of an ASB4 protein consisting of 8 to consecutive amino acids in the amino acid sequence of the protein, the second amino acid from the N terminal being leucine, isoleucine, or methionine, and/or the amino acid at the C terminal being valine, leucine, or isoleucine;
(2) a peptide which, in the partial peptide defined in (1), the second amino acid from the N terminal being replaced by leucine, isoleucine or methionine, and/or the amino acid at the C terminal being replaced by valine, leucine or isoleucine;
(3) a partial peptide of the ASB4 protein consisting of 8 to 14 consecutive amino acids in the amino acid sequence of the protein, the second amino acid from the N terminal being tyrosine, phenylalanine, methionine, or tryptophan, and/or the amino acid at the C terminal being leucine, isoleucine, or phenylalanine;
or
(4) a peptide which, in the partial peptide defined in (3), the second amino acid from the N terminal being replaced by tyrosine, phenylalanine, methionine or tryptophan, and/or the amino acid at the C terminal being replaced by leucine, isoleucine or phenylalanine;
and,
Y0 and Z0 are mutually independently a peptide consisting of 0 to several amino acids.

5 more elements

Dependencies are inferred from the claim text.

Tumor antigen peptide

Life of this patent

Tumor antigen peptide

Life of this patent

Abstract

Claims42